Skip to main content
Erschienen in: Familial Cancer 3/2022

20.10.2021 | Original Article

Identification of women at risk of hereditary breast–ovarian cancer among participants in a population-based breast cancer screening

verfasst von: Luigina Bonelli, Ivana Valle, Ivana Rebora, Paola Ricci, Lidia Biocchi, Giovanna Bruschi, Sabrina Parodi, Carla Bruzzone, Liliana Varesco

Erschienen in: Familial Cancer | Ausgabe 3/2022

Einloggen, um Zugang zu erhalten

Abstract

Women attending mammography screening may benefit from family history (FH) assessment for the identification of Hereditary Breast Ovarian Cancer (HBOC). Few studies explored the efficacy of tailored educational interventions in driving the attention on FH-associated risk among these women. To compare the efficacy of two educational tools in increasing attention towards FH, 6.802 women with a negative mammography were randomized to receive a note on FH of breast/ovarian cancer (letter A, n = 3.402) or a note with details on possible implication of FH patterns (letter B, n = 3.200). Upon women’s request, a brief questionnaire was administered on phone at the Screening Unit (S.U.) to select those eligible for an in-depth FH evaluation at the Genetic Unit (G.U.). Each affected relative was scored 1–3 according to type of cancer, age at diagnosis, gender, position in the family tree. In all, 401 women contacted the S.U.: 244 (6.6%) in group A and 177 (5.2%) in group B (adjOR 1.27; 95%CI 1.03–1.56). FH scored ≥ 3 for 164 women: 177 (47.5%) in group B and 224 (35.7%) in group A, (adjOR 1.59, 95%CI 1.06–2.38). The G.U. traced and interviewed 148 women, 65 (43.9%) were offered an in-person consultation: 38 attended and 30 were eligible for testing. A test was performed for 24 women: no BRCA pathogenic variant was found. Among mammographic screening attendees, educational material with a simple description of FH may improve self-referral of women deserving an in-depth evaluation for HBOC identification. Additional educational efforts are needed to enhance the efficiency of the intervention.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
6.
7.
Zurück zum Zitat Hu C, Polley EC, Yadav S, Lilyquist J, Shimelis H, Na J, Hart SN, Goldgar DE, Shah S, Pesaran T, Dolinsky JS, LaDuca H, Couch FJ (2020) The contribution of germline predisposition gene mutations to clinical subtypes of invasive breast cancer from a clinical genetic testing cohort. J Natl Cancer Inst. https://doi.org/10.1093/jnci/djaa023. Hu C, Polley EC, Yadav S, Lilyquist J, Shimelis H, Na J, Hart SN, Goldgar DE, Shah S, Pesaran T, Dolinsky JS, LaDuca H, Couch FJ (2020) The contribution of germline predisposition gene mutations to clinical subtypes of invasive breast cancer from a clinical genetic testing cohort. J Natl Cancer Inst. https://​doi.​org/​10.​1093/​jnci/​djaa023.
8.
Zurück zum Zitat US Preventive Services Task Force, Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, Caughey AB, Doubeni CA, Epling JW Jr, Kubik M, Landefeld CS, Mangione CM, Pbert L, Silverstein M, Simon MA, Tseng CW, Wong JB (2019) Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer: US preventive services task force recommendation statement. JAMA 322:652–665. https://doi.org/10.1001/jama.2019.10987CrossRef US Preventive Services Task Force, Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, Caughey AB, Doubeni CA, Epling JW Jr, Kubik M, Landefeld CS, Mangione CM, Pbert L, Silverstein M, Simon MA, Tseng CW, Wong JB (2019) Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer: US preventive services task force recommendation statement. JAMA 322:652–665. https://​doi.​org/​10.​1001/​jama.​2019.​10987CrossRef
10.
Zurück zum Zitat Azzollini J, Scuvera G, Bruno E, Pasanisi P, Zaffaroni D, Calvello M, Pasini B, Ripamonti CB, Colombo M, Pensotti V, Radice P, Peissel B, Manoukian S (2016) Mutation detection rates associated with specific selection criteria for BRCA1/2 testing in 1854 high-risk families: a monocentric Italian study. Eur J Intern Med 32:65–71. https://doi.org/10.1016/j.ejim.2016.03.010CrossRefPubMed Azzollini J, Scuvera G, Bruno E, Pasanisi P, Zaffaroni D, Calvello M, Pasini B, Ripamonti CB, Colombo M, Pensotti V, Radice P, Peissel B, Manoukian S (2016) Mutation detection rates associated with specific selection criteria for BRCA1/2 testing in 1854 high-risk families: a monocentric Italian study. Eur J Intern Med 32:65–71. https://​doi.​org/​10.​1016/​j.​ejim.​2016.​03.​010CrossRefPubMed
12.
Zurück zum Zitat Dimitrova N, Saz Parkinson Z, Bramesfeld A, Uluturk Tekin A, Bocchi G, Pylkkanen L, Lopez Alcalde J, Neamtiu L, Ambrosio M, Deandrea S, Lerda D (2016) European guidelines for breast cancer screening and diagnosis—The European Breast Guidelines. EUR 28360 EN. Luxembourg (Luxembourg): Publications Office of the European Union. JRC104007 Dimitrova N, Saz Parkinson Z, Bramesfeld A, Uluturk Tekin A, Bocchi G, Pylkkanen L, Lopez Alcalde J, Neamtiu L, Ambrosio M, Deandrea S, Lerda D (2016) European guidelines for breast cancer screening and diagnosis—The European Breast Guidelines. EUR 28360 EN. Luxembourg (Luxembourg): Publications Office of the European Union. JRC104007
18.
Zurück zum Zitat Blanch J, Sala M, Ibáñez J, Domingo L, Fernandez B, Otegi A, Barata T, Zubizarreta R, Ferrer J, Castells X, Rué M, Salas D; INCA Study Group (2014). Impact of risk factors on different interval cancer subtypes in a population-based breast cancer screening programme. PLoS ONE. 9(10):e110207. https://doi.org/10.1371/journal.pone.0110207. Blanch J, Sala M, Ibáñez J, Domingo L, Fernandez B, Otegi A, Barata T, Zubizarreta R, Ferrer J, Castells X, Rué M, Salas D; INCA Study Group (2014). Impact of risk factors on different interval cancer subtypes in a population-based breast cancer screening programme. PLoS ONE. 9(10):e110207. https://​doi.​org/​10.​1371/​journal.​pone.​0110207.
21.
Zurück zum Zitat My Pebs international randomized study comparing personalized, risk-stratified to standard breast cancer screening in women aged 40-70. ClinicalTrials.gov Identifier: NCT03672331 http://www.MyPeBS.eu/ My Pebs international randomized study comparing personalized, risk-stratified to standard breast cancer screening in women aged 40-70. ClinicalTrials.gov Identifier: NCT03672331 http://​www.​MyPeBS.​eu/​
22.
Zurück zum Zitat Cortesi L, Baldassarri B, Ferretti S, Razzaboni E, Bella M, Bucchi L, Canuti D, De Iaco P, De Santis G, Falcini F, Galli V, Godino L, Leoni M, Perrone AM, Pignatti M, Saguatti G, Santini D, Sassoli de’Bianchi P, Sebastiani F, Taffurelli M, Tazzioli G, Turchetti D, Zamagni C, Naldoni C (2020) A regional population-based hereditary breast cancer screening tool in Italy: first 5-year results. Cancer Med. https://doi.org/10.1002/cam4.2824CrossRefPubMedPubMedCentral Cortesi L, Baldassarri B, Ferretti S, Razzaboni E, Bella M, Bucchi L, Canuti D, De Iaco P, De Santis G, Falcini F, Galli V, Godino L, Leoni M, Perrone AM, Pignatti M, Saguatti G, Santini D, Sassoli de’Bianchi P, Sebastiani F, Taffurelli M, Tazzioli G, Turchetti D, Zamagni C, Naldoni C (2020) A regional population-based hereditary breast cancer screening tool in Italy: first 5-year results. Cancer Med. https://​doi.​org/​10.​1002/​cam4.​2824CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Meinert CL (1986) Clinical trials: design, conduct and analysis. . Oxford University Press, OxfordCrossRef Meinert CL (1986) Clinical trials: design, conduct and analysis. . Oxford University Press, OxfordCrossRef
26.
Zurück zum Zitat Varesco L, Viassolo V, Viel A, Gismondi V, Radice P, Montagna M, Alducci E, Della Puppa L, Oliani C, Tommasi S, Caligo MA, Vivanet C, Zuradelli M, Mandich P, Tibiletti MG, Cavalli P, Lucci Cordisco E, Turchetti D, Boggiani D, Bracci R, Bruzzi P, Bonelli L (2013) Performance of BOADICEA and BRCAPRO genetic models and of empirical criteria based on cancer family history for predicting BRCA mutation carrier probabilities: a retrospective study in a sample of Italian cancer genetics clinics. Breast 22:1130–1135. https://doi.org/10.1016/j.breast.2013.07.053CrossRefPubMed Varesco L, Viassolo V, Viel A, Gismondi V, Radice P, Montagna M, Alducci E, Della Puppa L, Oliani C, Tommasi S, Caligo MA, Vivanet C, Zuradelli M, Mandich P, Tibiletti MG, Cavalli P, Lucci Cordisco E, Turchetti D, Boggiani D, Bracci R, Bruzzi P, Bonelli L (2013) Performance of BOADICEA and BRCAPRO genetic models and of empirical criteria based on cancer family history for predicting BRCA mutation carrier probabilities: a retrospective study in a sample of Italian cancer genetics clinics. Breast 22:1130–1135. https://​doi.​org/​10.​1016/​j.​breast.​2013.​07.​053CrossRefPubMed
28.
Zurück zum Zitat Silver E, Wenger N, Xie Z, Elashoff D, Lee K, Madlensky L, Trent J, Petruse A, Johansen L, Naeim A (2019) Implementing a population-based breast cancer risk assessment program. Clin Breast Cancer 19:246–253CrossRef Silver E, Wenger N, Xie Z, Elashoff D, Lee K, Madlensky L, Trent J, Petruse A, Johansen L, Naeim A (2019) Implementing a population-based breast cancer risk assessment program. Clin Breast Cancer 19:246–253CrossRef
Metadaten
Titel
Identification of women at risk of hereditary breast–ovarian cancer among participants in a population-based breast cancer screening
verfasst von
Luigina Bonelli
Ivana Valle
Ivana Rebora
Paola Ricci
Lidia Biocchi
Giovanna Bruschi
Sabrina Parodi
Carla Bruzzone
Liliana Varesco
Publikationsdatum
20.10.2021
Verlag
Springer Netherlands
Erschienen in
Familial Cancer / Ausgabe 3/2022
Print ISSN: 1389-9600
Elektronische ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-021-00281-x

Weitere Artikel der Ausgabe 3/2022

Familial Cancer 3/2022 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.